Booth Bruce's Form 4/A amendment
AmendedKymera Therapeutics, Inc. (KYMR) · filed Jul 2, 2026
- Accession no.
- 0001451612-26-000022
- Filed
- Jul 2, 2026, 5:39 PM ET
- Trade date
- Jun 29, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jun 30, 2026
This filing lists 14 non-derivative transactions. Open-market sales total $8.28M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Booth BruceCIK 0001451612 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Common Stock | SSaleDisposed | −5,549 | $105.78F3 | −$586,973.22 | 2,446,375 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −14,798 | $106.63F5 | −$1,577,910.74 | 2,431,577 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −19,419 | $107.76F6 | −$2,092,591.44 | 2,412,158 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −10,848 | $108.28F7 | −$1,174,621.44 | 2,401,310 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −7,968 | $109.75F8 | −$874,488 | 2,393,342 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −7,723 | $110.67F9 | −$854,704.41 | 2,385,619 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −934 | $111.20F10 | −$103,860.8 | 2,384,685 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −770 | $105.78F3 | −$81,450.6 | 471,497 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −2,133 | $106.63F5 | −$227,441.79 | 469,364 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −2,698 | $107.76F6 | −$290,736.48 | 466,666 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −1,498 | $108.28F7 | −$162,203.44 | 465,168 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −1,104 | $109.75F8 | −$121,164 | 464,064 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −1,078 | $110.67F9 | −$119,302.26 | 462,986 | Indirect | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −130 | $111.20F10 | −$14,456 | 462,856 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
- F2
The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).
Referenced by the price of 2 transactions in Table I.
- F4
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.
Referenced by the price of 2 transactions in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.
Referenced by the price of 2 transactions in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive.
Referenced by the price of 2 transactions in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.
Referenced by the price of 2 transactions in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.
Referenced by the price of 2 transactions in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.
Referenced by the price of 2 transactions in Table I.
- F11
The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
Remarks
This Amendment is being filed to address an inadvertent clerical error in the original Form 4 relating to the allocation of the reported sales between Atlas Venture Fund X and AVOF. The aggregate number of shares sold by Atlas Venture Fund X and AVOF, as reported in the original Form 4, remains unchanged.